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Intracellular Ca 2ϩ overload is suggested to be one of the main factors involved in I/R injury. Because the sarcoplasmic reticulum (SR) plays a critical role in regulating cytosolic Ca 2ϩ concentration and subsequent cardiac contractility and relaxation, the dysfunction of cardiac SR Ca 2ϩ -pump ATPase (SERCA2a) during I/R may contribute to Ca 2ϩ overload and thereby affect the extent of contractile dysfunction that follows ischemia (23, 38 (12, 28) . Thus an alteration in the phosphorylation status of PLB residues during I/R should influence the consequent changes in SR Ca 2ϩ -pump ATPase activity and SR Ca 2ϩ uptake (20, 23) . There is evidence that ischemic preconditioning, which is associated with cardiopro-tection against I/R injury, attenuates I/R-induced depression in cardiac SR function and gene/protein expression including SERCA2a and PLB (22, 30) . Recently, Wang et al. (33) demonstrated that IHA hypoxia prevents an I/R-induced decrease in cardiac SR Ca 2ϩ release channel. However, it is unknown whether IHA hypoxia alters PLB phosphorylation status and SR Ca 2ϩ -pump ATPase activity in I/R hearts and, if it does, whether this alteration contributes to the cardioprotection of IHA hypoxia.
In the present study, we have compared the time-dependent changes in PLB phosphorylation status at Ser 16 and Thr 17 in normoxic and IHA hypoxic rat hearts during I/R and determined the possible role of such changes on IHA hypoxiainduced contractile recovery after ischemia. Animals. Male Sprague-Dawley rats were exposed to IHA hypoxia in a hypobaric chamber for one 6-h period each day for 42 days. Their body weights during this period rose from 100 -130 g to 290 -310 g. Barometric pressure (P B) was lowered to the level equivalent to that at an altitude of 5,000 meters (PB ϭ 404 mmHg, PO2 ϭ 84 mmHg). Age-matched control (normoxic) animals were kept under the normoxic environment for a corresponding time period. Their body weights and gains were identical to those in the group exposed to the IHA hypoxia. All animals had free access to water and a standard laboratory diet.
MATERIALS AND METHODS

Animals
Heart perfusions. Rats were anesthetized with pentobarbital sodium (60 mg/kg ip). The hearts were rapidly excised and perfused with Krebs-Henseleit solution at 37°C by using the Langendorff technique at a constant pressure of 80 mmHg, as previously described (33, 37) . The perfusion solution containing (in mM) 118 NaCl, 4.7 KCl, 1.2 MgSO 4 ⅐ 7H2O, 2.5 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 0.026 Na2-EDTA, and 11.1 glucose was gassed with 95% O2-5% CO2 (pH 7.4). For measuring the mechanical activity of the heart, a latex balloon connected to a pressure transducer (Gould model P23 Db, AD Instrument, Castle Hill, Australia) was inserted into the left ventricle. The balloon was filled with aqueous solution to achieve a left ventricular end-diastolic pressure (LVEDP) of 5-7 mmHg during initial equilibration. Contractile performance of the left ventricle was evaluated on the basis of its developed pressure (LVDP), the LVEDP, the maximal rate of pressure development (ϩdP/dt), and the maximal rate of pressure decay (ϪdP/dt). These parameters were monitored and analyzed with PowerLab (AD Instrument).
Experimental protocol. After stabilization, hearts were perfused for 10 additional minutes (preischemia) and were then subjected to 30 min of no-flow global ischemia (I30) followed by 30 min of reperfusion (R30), as shown in Fig. 1A . For the nonischemic control groups, the hearts were perfused for a comparable period with the oxygenated medium and then freeze-clamped at different times to match either the different ischemic or reperfusion periods with the studies on the association between PLB phosphorylation status and Ca 2ϩ -pump ATPase activity. Because basal values of PLB phosphorylation status and Ca 2ϩ -pump ATPase activity did not change with time, they were considered as a single group for statistical analysis. To test whether inhibitors of either PKA or CaMKII attenuate the beneficial effects of IHA hypoxia against I/R, we used H-89 (Calbiochem) and KN-93 (Sigma), respectively. When such reagents were used, either their corresponding vehicle or each inhibitor (H-89, 20 M or KN-93, 1 M) was delivered by an infusion pump into the perfusion stream above the aortic cannula at 1 ml/min (11, 32) . Inhibitors were perfused for 5 min before ischemia, ending at the first minute of reperfusion (H-89) or during reperfusion (KN-93). At the end of the experiments, the hearts were freeze-clamped and stored at Ϫ80°C until used in assays performed later.
Preparation of SR vesicles. The SR vesicles were prepared as described previously (20, 22, 23) . Briefly, the left ventricular tissue was homogenized in an extraction buffer containing (in mM) 10 NaHCO3, 5 NaN3, and 15 Tris ⅐ HCl (pH 6.8) with a Polytron PT 3100 homogenizer. The homogenate was centrifuged for 10 min at 11,000 g to remove cellular debris. The supernatant was centrifuged at 45,000 g for 45 min. The pellet was suspended in 8 ml of 600 mM KCl and 10 mM Tris ⅐ HCl (pH 6.8) and centrifuged at 45,000 g for 45 min. The final pellet was resuspended in 1 ml of 250 mM sucrose and 10 mM histidine buffer. The concentration of the SR membrane proteins was determined using the Bradford method. The yield was 1-2 mg membrane vesicles protein/g cardiac tissue.
Determination of SR Ca 2ϩ -pump ATPase activities. The SR Ca 2ϩ -pump ATPase activities were determined colorimetrically by measuring the inorganic phosphate (Pi) liberated from ATP hydrolysis according to a previously described method (6, 22) . Briefly, total (Mg 2ϩ and Ca 2ϩ ) and basal (Mg 2ϩ ) Ca 2ϩ -pump ATPase activities were determined in the presence or absence of Ca 2ϩ by using a Ca 2ϩ -pump ATPase enzyme assay kit (Jiancheng Bioengineering Institute, Nanjing, China). Mg 2ϩ -dependent (basal) ATPase activity was assayed in a reaction medium containing (in mM) 20 Tris ⅐ HCl, 5 MgCl2, 100 KCl, 5 NaN3, and 1 EGTA. Total Ca 2ϩ -pump ATPase activity was assayed in a similar medium, except that EGTA was replaced with 0.05 mM CaCl2. The reaction was started by the addition of 5 mM Tris ⅐ ATP in the presence of 20 g of SR protein and was terminated with 12% trichloroacetic acid. Pi liberated during the reaction was estimated in the protein-free supernatant. The Ca 2ϩ -stimulated, Mg 2ϩ -dependent ATPase (Ca 2ϩ -pump ATPase) activity was calculated as the difference between the total and basal ATPase activities.
Western blot analysis. The detection of PLB was performed as described previously (14) . Briefly, ϳ100 mg of freeze-clamped left ventricular tissue were homogenized at 4°C with a homogenizer in 10 vols of buffer containing (in mM) 5 histidine-HCl (pH 7.4), 10 EDTA, 50 Na4P2O7, 25 NaF, 0.2 dithiothreitol, and 0.1 phenylmethylsulfonyl fluoride. The concentration of protein was determined using the Bradford method. The homogenates were stored at Ϫ80°C. Thirty micrograms of homogenate protein per lane were resolved by performing urea SDS-PAGE with 7.5% (wt/vol) acrylamide gels. Proteins were electrophoretically transferred to a polyvinylidene difluoride membrane (Bio-Rad) and probed with the total PLB antibody anti-phospholamban A1 (1:2,000 dilution; Upstate Biotechnology) or the phosphorylation site-specific PS-16 and PS-17 PLB antibodies (1:10,000 dilution; Phosphoprotein Research, Leeds, UK). The membranes were then incubated with peroxidase-conjugated goat anti-mouse IgG (1:2,000 dilution; Sigma) or peroxidase-conjugated goat anti-rabbit IgG (1:15,000 dilution; Jackson ImmunoResearch). The immunoreaction was visualized using an enhanced chemiluminescent detection kit (Amersham Pharmacia Biotech, Amersham, UK), exposed to X-ray film, and quantified with a video documentation system (Gel Doc 2000; Bio-Rad). After exposure to a second antibody and luminescent detection of PLB phosphorylation status, the membrane was then stripped and exposed to anti-phospholamban A1 to detect total PLB to ensure equivalent protein loading. The signal intensity of the bands was quantified using optical densitometry analysis. Total PLB was expressed as a percentage of control densitometry. The phosphorylation of PLB was expressed as a percentage of isoproterenol-induced Ser 16 or Thr 17 phosphorylation at 30 nM, a concentration that produces maximal phosphorylation of PLB residues and mechanical response (19) , running in parallel with each experimental series.
Statistical analysis. Data are expressed as means Ϯ SE. Statistical significance was determined using ANOVA or repeated ANOVA for multiple comparisons or repeated measurements. Significant differences between the two mean values were estimated using Student's t-test (SPSS 11.5). A P value Ͻ0.05 was considered statistically significant.
RESULTS
Effect of IHA hypoxia on left ventricular function during I/R.
The time courses of changes in left ventricular function of the normoxic and IHA hypoxic groups with or without I/R are shown in Fig. 1B . During the preischemic phase, IHA hypoxia did not affect the LVDP, LVEDP, ϩdP/dt, and ϪdP/dt. During no-flow ischemia, LVDP, ϩdP/dt, and ϪdP/dt declined to zero, whereas LVEDP increased in both normoxic and IHA hypoxic hearts. However, in IHA hypoxic hearts, the maximum extent of ischemic contracture was significantly lower compared with that in normoxic hearts (74.1 Ϯ 1.4 vs. 83.1 Ϯ 2.2 mmHg, P Ͻ 0.01). During the reperfusion phase, IHA hypoxia significantly improved recovery of cardiac contractility. After 30 min of reperfusion of the ischemic hearts, the recovery of LVDP, ϩdP/dt, and ϪdP/dt in each group (normoxia vs. IHA hypoxia) was 19.6 Ϯ 1.8 vs. 37.6 Ϯ 2.7%, 18.4 Ϯ 0.5 vs. 40.1 Ϯ 3.9%, and 20.4 Ϯ 0.8 vs. 39.9 Ϯ 3.0% of preischemic values (P Ͻ 0.01 each), respectively. Concomitantly, this was associated with a marked decrease of LVEDP in the IHA hypoxic group (50.6 Ϯ 3.9 mmHg) compared with that in the normoxic group (73.2 Ϯ 4.6 mmHg, P Ͻ 0.01).
Time course of PLB protein content and Ser 16 /Thr 17 phosphorylation of PLB during I/R. To gain insight into the effect of IHA hypoxia on PLB, we determined the time course of the Fig. 1 . Experimental protocol and left ventricular (LV) function during ischemia-reperfusion (I/R) in normoxic and intermittent high-altitude (IHA) hypoxic rat hearts. A: experimental protocol. After stabilization, rat hearts were perfused for 10 additional minutes (Pre) and then subjected to 30 min of no-flow global ischemia followed by 30 min of reperfusion. Arrows indicate time points at which hearts were removed for assays. B: cardiac performance during I/R in normoxic (n ϭ 5) and IHA hypoxic hearts (n ϭ 6). LVDP, LV developed pressures; LVEDP, LV end-diastolic pressure; ϩdP/dt, maximal rate of LV pressure development; ϪdP/dt, maximal rate of LV pressure decline. C: maximal extent of ischemic contracture during ischemia in normoxic and IHA hypoxic hearts in the presence or absence of H-89 or KN-93. Values are means Ϯ SE (n ϭ 4 -14). *P Ͻ 0.05; **P Ͻ 0.01 vs. corresponding normoxia values.
total PLB expression and its phosphorylation status during I/R in normoxic and IHA hypoxic left ventricles. The data correspond to the same hearts in which cardiac function was evaluated. Figure 2 represents immunoblots and densitometric evaluations of total protein content of PLB. No significant difference in total PLB was detected between normoxic and IHA hypoxic hearts with or without I/R. Figure 3 shows the time course of changes in the phosphorylation status of PLB at Ser 16 and Thr 17 during I/R in normoxic and IHA hypoxic hearts. In normoxic hearts, Ser 16 phosphorylation significantly increased at I30 by 188.8 Ϯ 12.6% and after 1 min of reperfusion (R1) by 220.1 Ϯ 10.9% of preischemic values, respectively (P Ͻ 0.01), but decreased to a level lower than that during preischemia by R30 (P Ͻ 0.01). In IHA hypoxic hearts, Ser 16 phosphorylation in the preischemic phase was unchanged compared with that in normoxic hearts. However, I/R-induced increases in the phosphorylation status of this residue in hypoxic hearts were significantly higher (increased at I30 by 252.1 Ϯ 19.9% and at R1 276.6 Ϯ 30.4% of preischemic values, respectively, P Ͻ 0.05) compared with normoxic values, whereas I/R-induced depression at R30 remained unchanged (Fig. 3A) .
In normoxic hearts, phosphorylation of PLB at Thr end of ischemia and during postischemic reperfusion by 54.3 Ϯ 4.2% (I30), 38.4 Ϯ 2.9% (R1), and 55.4 Ϯ 2.8% (R30), respectively (P Ͻ 0.01) in normoxic hearts. The depression was more significant at I30 and R30. However, these changes were significantly attenuated in hearts exposed to IHA hypoxia (34.3 Ϯ 5.3% at I30, 26.7 Ϯ 4.7% at R1, and 44.1 Ϯ 1.3% at R30, P Ͻ 0.05; Fig. 4) .
Relative contribution of PKA to IHA hypoxia-induced protection against I/R injury. Because it is well established that the phosphorylation status of PLB at Ser
16 is exclusively mediated by the PKA pathway, we used the PKA inhibitor H-89 to study the relationship between phosphorylation of PLB at Ser 16 and the dependence of mechanical recovery on exposure to IHA hypoxia during I/R. H-89 completely abolished the increased phosphorylation of PLB Ser 16 at R1 in both normoxic and IHA hypoxic hearts (Fig. 5, A and B) . Consistently, H-89 inhibited SR Ca 2ϩ -pump ATPase activities and postischemic recovery of cardiac relaxation in normoxic hearts and abolished the beneficial effect of IHA hypoxia on these parameters (Fig. 5, C  and D) , although it did not affect preischemic contractile and relaxation parameters in both groups (data not shown). No significant difference in the maximum extent of ischemic contracture was detected with or without H-89 in both normoxic and IHA hypoxic hearts (Fig. 1C) .
Relative contribution of CaMKII to IHA hypoxia-induced protection against I/R injury. Site-specific phosphorylation of PLB at Thr 17 is mediated by the CaMKII pathway. To evaluate the contribution by this pathway to inducement of the beneficial effects of IHA hypoxia, we determined in I/R hearts the effects of KN-93, a CaMKII-specific inhibitor, on Thr 17 phosphorylation of PLB, SR Ca 2ϩ -pump ATPase activity, and cardiac function. KN-93 did not affect preischemic contractile and relaxation in normoxic and IHA hypoxic hearts (data not shown). In contrast, Fig. 6 shows that KN-93 completely abolished the IHA hypoxia-induced increase in Thr 17 phosphorylation of PLB and SR Ca 2ϩ -pump ATPase activity at R30 but had no effect in normoxic hearts (Fig. 6, A-C) . These inhibitory effects were associated with an abolishment by KN-93 of the improved recovery of cardiac relaxation induced by IHA hypoxia, although KN-93 did not affect cardiac relaxation in normoxic hearts (Fig. 6D) . No significant difference in the maximum extent of ischemic contracture was detected with or without KN-93 in both normoxic and IHA hypoxia hearts (Fig. 1C) .
DISCUSSION
We evaluated changes in the phosphorylation status of PLB Ser 16 and Thr 17 during I/R in normoxic and IHA hypoxic rat hearts to determine whether IHA hypoxia-induced upregulation of PLB Ser 16 and Thr 17 phosphorylation improved contractile recovery after ischemia.
Effects of IHA hypoxia on Ser 16 and Thr 17 phosphorylation of PLB during I/R. The phosphorylation status of PLB in normoxic hearts is generally similar to that reported earlier (20, 32) . We report here for the first time the effect of IHA hypoxia on the time course of the phosphorylation of PLB Ser 16 and Thr 17 during I/R. The phosphorylation of PLB at Ser 16 and Thr 17 decreased at the end of reperfusion. However, at the end of ischemia and at the onset of reperfusion, there is dissociation between the changes in the phosphorylation status of these two residues, i.e., an increase in Ser 16 phosphorylation associated with a decrease in Thr 17 phosphorylation. The trend at the onset of reperfusion is contrary to that described by Vittone et al. (32) . They found, instead, an opposite dissociation between the phosphorylation of the two residues at the onset of reperfusion. This discrepancy may be caused by a difference in the duration of ischemia and/or experimental condition, because the ischemic time was 30 min in our protocol, whereas it was 20 min in that of Vittone et al. (32) . IHA hypoxia did not significantly affect total PLB protein levels or alter the pattern of changes in dual-site phosphorylation of PLB in I/R. However, it significantly enhanced the upregulation of PLB Ser 16 phosphorylation at the end of ischemia and at the onset of reperfusion and attenuated the decreased PLB Thr 17 phosphorylation during I/R.
The observed dissociated regulation of Ser 16 during I/R may be due to a depression in CaMK activity caused by intracellular Ca 2ϩ overload. This is supported by our observation that whereas CaMKII inhibitor did not affect depressed Thr 17 phosphorylation further in the normoxic heart, it completely inhibited the IHA hypoxia-improved Thr 17 phosphorylation. It also has been well documented that ischemia induces intracellular acidosis (3). Acidosis reduced PLB Ser 16 phosphorylation in the absence of isoproterenol, a ␤-adrenergic agonist, but did not alter the isoproterenol-induced Ser 16 phosphorylation (10) . Acidosis also increased intracellular Ca 2ϩ levels (7) and inhibited activity of protein phosphatase 1 (PP1), a major phosphatase that dephosphorylates PLB in the rat myocardium (18) . In addition, ischemia induced the increases in the activation of the ␤-adrenergic system and norepinephrine level (32) . This is consistent with our observation that increased Ser 16 phosphorylation could be completely inhibited by PKA inhibitor in either normoxic or IHA hypoxic hearts. Thus the dissociation between the Ser 16 and Thr 17 phosphorylation of PLB during I/R is the consequence of different mechanisms triggered by Ca 2ϩ overload, acidosis, and the ␤-adrenergic system. It seems that the increase in Ser 16 phosphorylation may be induced mainly by enhanced PKA activity as well as an inhibition in PP1 caused by acidosis. The decrease in Thr 17 phosphorylation is more likely caused by a depression in CaMKII activity, a consequence of Ca 2ϩ overload and acidosis. However, increased PP1 activity also may be involved in the reduction of dual-site PLB phosphorylation during reperfusion in the prolonged ischemia myocardium (9) . Therefore, further studies are required to clarify these issues by determining the alteration of the balance between the kinases (PKA and CaMKII) and PP1 during I/R in normoxic and IHA hypoxic heart.
Effects of IHA hypoxia on inhibited SR Ca 2ϩ -pump ATPase activity during I/R. Cytosolic Ca 2ϩ concentration in cardiomyocytes is dependent on the ability of SR Ca 2ϩ -pump ATPase to mediate Ca 2ϩ uptake into the SR lumen. Dysfunctional transport activity is considered to be one of the major determinants of I/R injury (4). It has been observed that ischemic preconditioning exerts beneficial effects on I/R-induced alterations in SR Ca 2ϩ handling abilities. This can occur through prevention of changes in SR gene/protein expression and activities (22, 23) . A previous study in our laboratory (37) demonstrated that IHA hypoxia-induced mitigating effects on I/R-induced alterations in postischemic contractility are accompanied by a significant decrease in intracellular Ca 2ϩ overload during I/R. Wang et al. (33) reported that IHA hypoxia prevents I/Rinduced suppression of maximal binding sites of cardiac SR Ca 2ϩ release channels/ryanodine receptors. We thus proposed that IHA hypoxia may attenuate I/R-induced Ca 2ϩ overload by reducing alterations in SR function. The present data show that IHA hypoxia adaptation did not change the activity of SR Ca 2ϩ -pump ATPase in the preischemic period but attenuated I/R-induced reduction in its enzymatic activity via PKA and CaMKII pathways.
Importantly, we have identified the relationship between the IHA hypoxia-induced alteration of PLB phosphorylation and SR Ca 2ϩ -pump ATPase activity during I/R. The function of SR Ca 2ϩ -pump ATPase is critically regulated by the PLB phosphorylation status. Dephosphorylated PLB inhibits SR Ca 2ϩ -pump ATPase activity, whereas phosphorylation of PLB by either cAMP-dependent PKA at Ser 16 residue or by CaMKII at Thr 17 residue relieves this inhibition, resulting in an increase in Ca 2ϩ -pump ATPase (12, 28, 29) . It has been proposed that I/R-induced phosphorylation of PLB and a consequent decrease in PLB inhibition of Ca 2ϩ -pump ATPase serve to decrease cytosolic Ca 2ϩ overload by increasing sequestration of Ca 2ϩ into the SR, which might be a protective mechanism (27, 32) . This is supported by the observation that both of the aforementioned PLB phosphorylation sites are involved in the mechanical recovery after ischemia (32) -pump ATPase activity by increasing dual-site PLB phosphorylation during I/R through PKA and CaMKII pathways.
Role of Ser 16 and Thr 17 PLB phosphorylation on IHA hypoxia-induced mechanical recovery of I/R heart. PLB is a key regulator of basal contractility in the mammalian heart (15) . Recent studies (27) demonstrated that changes in the phosphorylation status of PLB at both Ser 16 and Thr 17 are involved in the contractile recovery after ischemia. However, the functional significance of dual-site PLB phosphorylation in the mechanism of IHA hypoxia-induced cardioprotection of contractility after ischemia has not been previously evaluated. The present studies were therefore designed to address this issue. The results demonstrate for the first time that in IHA hypoxic hearts, both upregulated Ser 16 and Thr 17 phosphorylation of PLB contribute to the improved functional recovery after ischemia, but Thr 17 phosphorylation plays a major role throughout the reperfusion period.
It is noteworthy that IHA hypoxia-increased Thr 17 phosphorylation of PLB is associated with improved recovery of mechanical function at R30, but IHA hypoxia-increased Ser 16 and Thr 17 phosphorylation of PLB at R1 had no direct and immediate impact on the mechanical function, although SR Ca 2ϩ -pump ATPase activity improved. Moreover, at R30 there were significant decreases in SR Ca 2ϩ -pump ATPase activities compared with those at R1 in both groups, whereas myocardial function was still improving in the IHA hypoxia group. This indicates that mechanisms other than SR Ca 2ϩ -pump ATPase also underlie the improved recovery of function after an ischemic insult in IHA hypoxic animals, but preservation of SR function during ischemia and early reperfusion seems important for the later functional recovery. As has been suggested by others (32) , it could be that enhanced SR calcium uptake allows I/R myocytes to deal with transiently increased cytosolic Ca 2ϩ during the early reperfusion period, which would allow the myocytes to remain intact and allow other recovery mechanisms to occur. In this case, increased PLB phosphorylation would be indirectly associated with improved recovery. This is supported by the observation that inhibition of the transient increase in the Ser 16 phosphorylation status in the presence of H-89, used to inhibit PKA, was associated with significant inhibitions of Ca 2ϩ -pump ATPase activity and functional recovery during reperfusion.
Recently reported data (3) also have shown that ischemic injury is increased in PLB knockout mice. This suggests that PLB phosphorylation during I/R might be detrimental, because phosphorylation and ablation of PLB both result in increased SR Ca 2ϩ -pump ATPase activity. However, the present results indicate that abolishment of increased Ser 16 phosphorylation by the PKA-specific inhibitor H-89 was associated with an inhibition of the contractile recovery after ischemia in either the normoxic or IHA hypoxic hearts. Similarly, inhibition of IHA hypoxia-induced upregulated Thr 17 phosphorylation by the CaMKII-specific inhibitor KN-93 was accompanied by an abolishment of functional recovery. These results are consistent with the observation that mutation of either Ser 16 or Thr 17 phosphorylation diminished the contractile recovery after the ischemia (27) . Therefore, the presence of PLB phosphorylation sites improves, rather than impairs, the contractile recovery after ischemia, but permanent enhancement of SR Ca 2ϩ -pump ATPase activity in PLB knockout mice may impair the recovery. H-89 and KN-93 also could have inhibited the phosphorylation of other substrates of PKA and CaMKII, such as SR Ca 2ϩ -pump ATPase or ryanodine receptors; thus the possible involvement of other substrates of PKA and CaMKII in providing the protective effects of IHA hypoxic hearts needs to be considered. However, a previous study (16) in permeabilized myocytes has shown that the declines in SR Ca 2ϩ uptake induced by PKA and CaMKII inhibitors could be prevented by an antibody to PLB, suggesting that PLB is the critical substrate for PKA and CaMKII regulation of cardiac contractility. Taken together, these findings indicate that dual-site PLB phosphorylation is necessary for the contractile recovery after ischemia, because its regulation of Ca 2ϩ -pump ATPase activity plays an important role in the cardioprotection of IHA hypoxia via PKA and CaMKII pathways.
Interestingly, neither PKA nor CaMKII inhibition hindered the ability of IHA hypoxia to protect against the maximal ischemic contracture. Therefore, the protective effects of IHA hypoxia on this response are not mediated by PKA and CaMKII pathways. It has been proposed (31) that ischemic contracture may be caused by a lock in the rigor state as a result of a decrease in myocardial ATP or an increase in ADP. Because IHA hypoxia significantly accelerated the restoration of creatine phosphate, ATP, and creatine phosphokinase activity in reoxygenated myocardium following acute anoxia (13) , IHA hypoxic hearts may preserve cytosolic ATP content at higher levels than those in normoxic hearts. Accordingly, bioenergetics may be less impacted in IHA hypoxia, which could explain the decreased contracture response to ischemia and also the better recovery of postischemic contractile function in IHA hypoxic hearts.
Recent studies have shown that ATP-sensitive K ϩ channels, especially mitoK ATP , are involved in the cardioprotective effects of IHA hypoxia (1, 37) . It is possible that mitoK ATP may mediate the beneficial effects of IHA hypoxia by lessening Ca 2ϩ overload induced by I/R (37) . However, such a mechanism cannot explain the beneficial effects of IHA hypoxia against I/R-induced changes in SR function and in phosphorylation of PLB because the relationship between them is not understood. Therefore, the possible involvement of yet other protective mechanisms of IHA hypoxia against ischemia warrants future studies.
In conclusion, the present results provide the first evidence that IHA hypoxia upregulates the level of Ser 16 and Thr 17 phosphorylation of PLB in I/R hearts via activation of PKA and CaMKII pathways. These effects are beneficial because they lessen the declines in SR Ca 2ϩ -pump ATPase activity during I/R and, in turn, may contribute to the IHA hypoxiainduced contractile recovery after ischemia.
